Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

bioRxiv : the preprint server for biology·2026
Same author

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Blood advances·2026
Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2026
Same author

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.

Annals of hematology·2026
Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026
Same author

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Blood·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Peripheral T-cell lymphoma.

Francine M Foss1, Pier Luigi Zinzani, Julie M Vose

  • 1Yale Cancer Center, New Haven, CT, USA. francine.foss@yale.edu

Blood
|April 16, 2011
PubMed
Summary
This summary is machine-generated.

Peripheral T-cell lymphomas (PTCLs) are aggressive cancers with poor prognoses. Rare subtypes and a growing number of therapies necessitate collaborative research for effective treatment strategies.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Peripheral T-cell lymphomas (PTCLs) represent a diverse and aggressive group of lymphoid malignancies.
  • These cancers are characterized by poor patient outcomes and present significant challenges in clinical research due to subtype rarity.

Purpose of the Study:

  • To review current lymphoma classification systems, focusing on the International PTCL Project's contributions.
  • To discuss prognostic factors, gene expression profiling, and emerging therapeutic strategies for PTCL.

Main Methods:

  • Review of major lymphoma classification schemas, including the World Health Organization's 2008 update.
  • Analysis of contributions from the International PTCL Project.
  • Overview of current and investigational therapeutic modalities.

Main Results:

  • The rarity of PTCL subtypes complicates clinical trial enrollment and drug development.
  • A wide array of novel therapeutic agents are available, including antifolates, conjugates, and targeted inhibitors.
  • The challenge lies in matching patients to appropriate trials due to limited patient populations.

Conclusions:

  • Collaborative research efforts are crucial for advancing the understanding and treatment of PTCL.
  • Coordinated studies will facilitate the testing of numerous drugs and the identification of optimal treatment strategies.
  • Improving outcomes for patients with PTCL requires a unified approach to clinical research and drug evaluation.